Onkológia 1/2020

Impact of pricing regulations on access to innovative therapies

The importance of regulating the pricing of medicines is recognized by all countries of the EU, Slovakia not excluded. What makes the countries different from each other is the approach of the key authorities to their development and implementation. The comparison of 14 regulatory instruments in the selected European countries shows that the scope of use of regulatory instruments as well as the strictness of their application in Slovakia is unprecedented on a European scale. The outcome of such an approach is reflected in the standard availability of innovative drugs, which is limited, even when compared with economically weaker countries in the region.

Keywords: medicines policy, regulations, pricing of medicines, QALY, innovative drugs